156 related articles for article (PubMed ID: 38861890)
21. Association between the composite dietary antioxidant index and metabolic dysfunction-associated steatotic liver disease in adults: a cross-sectional study from NHANES 2017-2020.
Yang Z; Song S; Li L; Yuan Z; Li Y
Sci Rep; 2024 Jun; 14(1):13801. PubMed ID: 38877074
[TBL] [Abstract][Full Text] [Related]
22. Dietary characteristics associated with the risk of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease in non-obese Japanese participants: A cross-sectional study.
Taniguchi H; Ueda M; Sano F; Kobayashi Y; Shima T
JGH Open; 2024 May; 8(5):e13082. PubMed ID: 38779132
[TBL] [Abstract][Full Text] [Related]
23. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.
Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q
World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767
[TBL] [Abstract][Full Text] [Related]
24. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
[TBL] [Abstract][Full Text] [Related]
25. Effects of carnosine supplementation on markers for the pathophysiological development of metabolic dysfunction-associated steatotic liver disease in a diet-induced model.
Grandini NA; Costa MR; Gregolin CS; Siqueira JS; Vieira TA; Togneri Ferron AJ; Francisqueti-Ferron FV; Romualdo GR; Lúcia Dos Anjos Ferreira A; Aldini G; Corrêa CR; Moreto F
Mol Cell Endocrinol; 2024 Mar; 582():112138. PubMed ID: 38147954
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the Diagnostic Utility of Selected Serum Adipokines and Cytokines in Subjects with MASLD-A Pilot Study.
Zyśk B; Ostrowska L; Smarkusz-Zarzecka J; Orywal K; Mroczko B; Cwalina U
Nutrients; 2024 May; 16(9):. PubMed ID: 38732626
[TBL] [Abstract][Full Text] [Related]
27. Fatty Liver Index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men.
Crudele L; De Matteis C; Novielli F; Di Buduo E; Petruzzelli S; De Giorgi A; Antonica G; Berardi E; Moschetta A
Biol Sex Differ; 2024 May; 15(1):43. PubMed ID: 38760802
[TBL] [Abstract][Full Text] [Related]
28. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
Curr Obes Rep; 2024 May; ():. PubMed ID: 38809396
[TBL] [Abstract][Full Text] [Related]
29. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
[TBL] [Abstract][Full Text] [Related]
30. Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity.
Núñez-Sánchez MÁ; Martínez-Sánchez MA; Martínez-Montoro JI; Balaguer-Román A; Murcia-García E; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez-Cáceres CM; Sledzinski T; Frutos MD; Hernández-Morante JJ; Fernández-García JC; Queipo-Ortuño MI; Ruiz-Alcaraz AJ; Mika A; Ramos-Molina B
J Clin Endocrinol Metab; 2024 Jun; 109(7):1781-1792. PubMed ID: 38217869
[TBL] [Abstract][Full Text] [Related]
31. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
; ; ;
Diabetologia; 2024 Jun; ():. PubMed ID: 38869512
[TBL] [Abstract][Full Text] [Related]
32. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
Burmeister Y; Weyer K; Dörre A; Seilheimer B
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
[TBL] [Abstract][Full Text] [Related]
33. Dietary Inflammatory Index and liver status in subjects with different adiposity levels within the PREDIMED trial.
Cantero I; Abete I; Babio N; Arós F; Corella D; Estruch R; Fitó M; Hebert JR; Martínez-González MÁ; Pintó X; Portillo MP; Ruiz-Canela M; Shivappa N; Wärnberg J; Gómez-Gracia E; Tur JA; Salas-Salvadó J; Zulet MA; Martínez JA
Clin Nutr; 2018 Oct; 37(5):1736-1743. PubMed ID: 28734553
[TBL] [Abstract][Full Text] [Related]
34. Dietary macro and micronutrients associated with MASLD: Analysis of a national US cohort database.
Nemer M; Osman F; Said A
Ann Hepatol; 2024; 29(3):101491. PubMed ID: 38412922
[TBL] [Abstract][Full Text] [Related]
35. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
[TBL] [Abstract][Full Text] [Related]
36. Bioelectrical impedance parameters add incremental value to waist-to-hip ratio for prediction of metabolic dysfunction associated steatotic liver disease in youth with overweight and obesity.
Song K; Seol EG; Yang H; Jeon S; Shin HJ; Chae HW; Kim EK; Kwon YJ; Lee JW
Front Endocrinol (Lausanne); 2024; 15():1385002. PubMed ID: 38883602
[TBL] [Abstract][Full Text] [Related]
37. Trends in Oxidative Balance Score and Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in the United States: National Health and Nutrition Examination Survey 2001 to 2018.
Tan Z; Wu Y; Meng Y; Liu C; Deng B; Zhen J; Dong W
Nutrients; 2023 Nov; 15(23):. PubMed ID: 38068789
[TBL] [Abstract][Full Text] [Related]
38. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
[TBL] [Abstract][Full Text] [Related]
39. Exploring the landscape of steatotic liver disease in the general US population.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
[TBL] [Abstract][Full Text] [Related]
40. Adipocytokines as Predictors of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Development in Type 2 Diabetes Mellitus Patients.
Fajkić A; Jahić R; Hadžović-Džuvo A; Lepara O
Cureus; 2024 Mar; 16(3):e55673. PubMed ID: 38455340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
